After it was discovered that the dialysis products GranuFlo and Naturalyte can cause fatal heart attack, stroke, cardiac arrest, hyperkalemia, low blood pressure, and death, the FDA issued a class I recall of the products. Lawsuits filed in the United States District Court for the District of Massachusetts allege that Fresenius, the manufacturer of GranuFlo and Naturalyte, knew about the dangers associated with its products but failed to notify consumers. Meyerson & O’Neill will now be accepting cases on behalf of dialysis patients who received GranuFlo or Naturalyte and whose treatment may have caused them to suffer one of the serious injuries associated with these products.
During dialysis, a machine filters waste, salt, and water from the bodies of patients whose kidneys are not healthy enough to accomplish this task. Part of this process involves neutralizing acids found in the patient’s blood stream using a substance called bicarbonate. Unfortunately, the GranuFlo and Naturalyte products are defectively designed and or administered such that the patient receives and retains excessive bicarbonate which leads to metabolic alkalosis, a condition which can result in serious cardiac injuries including heart attack, stroke, and death.
The risks presented by GranuFlo and Naturalyte are catastrophic. Data shows that in 2010 alone over 900 Fresenius patients experienced cardiac arrest related to their dialysis treatments. If you or a loved one suffered a cardiac injury during or shortly after receiving GranuFlo or Naturalyte, please
contact one of our experienced GranuFlo or Naturalyte litigation attorneys at (215) 972-1376 for a free and confidential consultation. You may be entitled to monetary compensation.